HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · IEX Real-Time Price · USD
+0.07 (0.39%)
Jul 18, 2024, 3:59 PM EDT - Market closed

Company Description

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.

The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.

It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton’s tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms.

It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.

HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited
HUTCHMED (China) logo
Country Hong Kong
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,988
CEO Dr. Wei-Guo Su B.Sc., Ph.D.

Contact Details

48th Floor, Cheung Kong Center, 2 Queen's Road Central
Hong Kong, K3 00000
Hong Kong
Phone 852-2121-3888

Stock Details

Ticker Symbol HCM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001648257
CUSIP Number 44842L103
ISIN Number US44842L1035
SIC Code 2834

Key Executives

Name Position
Dr. Wei-Guo Su B.Sc., Ph.D. Chief Executive Officer, Chief Scientific Officer and Executive Director
Chi Keung To ACGI, B.Sc., M.B.A. Executive Chairman
Chig Fung Cheng BEc, CA Chief Financial Officer and Executive Director
Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E Company Secretary and Non-Executive Director
Dr. Karen Jane Atkin Executive Vice President and Chief Operating Officer
David Ng Head of Investor Relations and Capital Strategies
Charles George Rupert Nixon Group General Counsel
Kin Hung Lee M.B.A. Senior Vice President of Corporate Management and Communications
Selina Zhang Senior Vice President of Global Human Resources
Dr. Qingmei Wang Ph.D. Senior Vice President of Business Development and Strategic Alliances

Latest SEC Filings

Date Type Title
Jul 5, 2024 6-K Report of foreign issuer
Jun 28, 2024 6-K Report of foreign issuer
Jun 28, 2024 F-3ASR Filing
Jun 26, 2024 6-K Report of foreign issuer
Jun 24, 2024 6-K Report of foreign issuer
Jun 17, 2024 6-K Report of foreign issuer
Jun 7, 2024 6-K Report of foreign issuer
Jun 3, 2024 6-K Report of foreign issuer
May 31, 2024 6-K Report of foreign issuer
May 24, 2024 6-K Report of foreign issuer